One of the major challenges of early-stage breast cancer is to select the adjuvant therapy that ensures the most benefits and the least harm for the patient. The definition of accurate predictive factors is therefore of paramount importance. So far the choice of adjuvant therapy has been based on the number of affected lymph nodes and the hormone receptor status of the patient. This paper evaluates the use of other tumor-related markers as predictive factors for adjuvant therapy. These include HER2, p53 and Bcl-2, cathepsin B, p27, proliferating cell nuclear antigen (PCNA), cyclin D, Ki-67, and vascular endothelial growth factor (VEGF).
CITATION STYLE
Munster, P. N., & Norton, L. (2001). Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Research, 3(6), 361–364. https://doi.org/10.1186/bcr323
Mendeley helps you to discover research relevant for your work.